Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621430 | 0.88 | RXFP1 (0.41) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL430982 | 0.80 | KDM1A (0.33) | — | |
| SCHEMBL4222337 | 0.79 | RXFP1 (0.42) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL15765124 | 0.74 | RXFP1 (0.43) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL17843534 | 0.73 | RXFP1 (0.36) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL18305822 | 0.71 | GAA (0.41) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL4223370 | 0.70 | ALDH1A1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL5809840 | 0.70 | KDM4E (0.41) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL4222577 | 0.70 | KDM4E (0.41) | RXFP1KDM4EALDH1A1HPGD | |
| SCHEMBL28412403 | 0.70 | RXFP1 (0.40) | RXFP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | RXFP1 678/4885KDM4E 2318/4885ALDH1A1 190/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | RXFP1 678/4885KDM4E 2318/4885ALDH1A1 190/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | RXFP1 193/4885KDM4E 2246/4885ALDH1A1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.